Amunix

Amunix, now headquartered in Mountain View, California, focuses on developing prodrug therapies for immune activators to treat solid tumors. The company leverages its proprietary XPAT and XPAC technology platforms to develop a series of prodrug therapies that can be selectively released in the tumor microenvironment. Its two prodrug platform technologies have been clinically validated, demonstrating the ability to extend drug half-life while exhibiting very low immunogenicity. Amunix's lead program is a Her-2 targeted bispecific antibody prodrug developed using the XPAT technology platform, with multiple other programs, including an IL-12 XPAC product, currently under development.